Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 2Other hematologic neoplasm 1Dermatologic 1

Conditions

Lymphoma, T-Cell, Cutaneous 8Sezary Syndrome 5Mycosis Fungoides 5Lymphoma, Large B-Cell, Diffuse 5Lymphoma, B-Cell, Marginal Zone 5Hodgkin Disease 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Multiple Myeloma 4Lymphoma, T-Cell, Peripheral 4Lymphoma, Non-Hodgkin 4Lymphoma, Mantle-Cell 4Lymphoma, Large-Cell, Immunoblastic 4Lymphoma, Follicular 4Leukemia, Lymphocytic, Chronic, B-Cell 4Burkitt Lymphoma 4Melanoma 3Lymphoma 3Breast Neoplasms 3Waldenstrom Macroglobulinemia 2Vomiting 2Uveal Melanoma 2Testicular Neoplasms 2Primary Myelofibrosis 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Pdgfra-Associated Chronic Eosinophilic Leukemia 2Neuroblastoma 2Neoplasms 2Nausea 2Myeloproliferative Disorders 2Lymphoma, Large-Cell, Anaplastic 2

Interventions

denileukin diftitox 2Nivolumab 2sargramostim 1peginterferon alfa-2b 1Prednisone 1Phenobarbital 1Methylprednisolone Hemisuccinate 1Methylprednisolone 1Irinotecan 1Introns 1Infliximab 1Etoposide 1Dexamethasone 1Cyclosporine 1Cyclophosphamide 1Cisplatin 1Amifostine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Drug-Related Side Effects and Adverse Reactions × Dexamethasone × Dermatologic × Clear all
NCT00006345 2013-05-30

Dexamethasone Followed by Denileukin Diftitox in Treating Patients With Persistent or Recurrent T-Cell Lymphoma

National Cancer Institute (NCI)

Phase 2 Completed
DermatologicLymphoid

Lymphoma, Mycosis Fungoides, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous, Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡